Option chain shows key data for Roche Holding's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Roche Holding.

Roche Holding (OTC:RHHBY) Stock, Option Chain

Roche Holding

ROCHE HLDG LTD SPONS

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Konskie,,Poland,-,February,24,,2024:,Sarepta,Therapeutics,Company,Logo

Biotech

News

Health Care

Movers

General

RHHBY

SRPT

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause.

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy

Weight Loss Drugs

CHGCY

Chugai plans to pair its muscle-preserving drug with Eli Lilly&#39;s orforglipron, addressing muscle loss in obesity care as the market expands rapidly.

Eli Lilly&#39;s Obesity Drug Success Spurs Japanese Biotech&#39;s Anti-Muscle-Wasting Combo Therapy

Lab.Pharma.Pharmeuticals

JAZZ

Jazz Pharma&#39;s Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung cancer patients.

Jazz Pharma&#39;s Zepzelca Combo Shows Survival Edge In Lung Cancer Study

ROCHE HOLDING LTD S/ADR by Roche Holding Ltd

Roche Holding AG

Press Releases

Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

FDA Approves Genentech's Susvimo for Diabetic Retinopathy

New Two-year Follow-up of Genentech's Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients

Genentech's Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis

New Data Show Genentech's Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer

Genentech's Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer

Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease

Genentech Provides Update on Phase III Verona Study

Genentech's Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma

Roche's Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma

TD Cowen

Cowen & Co.

Comments

Roche Holding

Roche Holding (RHHBY) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell